Sumitomo Chemical India Ltd.
SUMICHEMCommodities filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
4 transcript(s)/analyst meet(s) served; 2 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 4 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20210606 | 2021-03-31 | yes | |
| TRANSCRIPT | 20230525 | 2023-03-31 | yes | |
| TRANSCRIPT | 20240603 | 2024-03-31 | yes | |
| DUPLICATE | 20240603 | 2024-03-31 | no | |
| TRANSCRIPT | 20241105 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250603 | 2025-03-31 | yes | |
| TRANSCRIPT | 20251103 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260604 | 2025-09-30 | yes | |
| DUPLICATE | 20260604 | 2026-03-31 | no |
SUMICHEM
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 449.70 |
| 52-week range | 364.45 – 564.95 |
| Return 1M | -13.77% |
| Return 3M | 3.31% |
| Return 1Y | -20.15% |
| Return 3Y | 5.7% |
| Return 5Y | 12.88% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 1,063.00 |
| Other income | 47.00 |
| Total income | 1,111.00 |
| Cost of materials consumed | 554.00 |
| Purchases of stock-in-trade | 132.00 |
| Changes in inventories | -40.00 |
| Employee benefit expense | 73.00 |
| Finance costs | 2.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.75 | 0.00 |
| institutions foreign | 0.03 | -0.00 |
| institutions domestic | 0.09 | 0.00 |
| mutual funds | 0.07 | 0.00 |
| public | 0.25 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| DUPLICATE | 2026-03-31 | 2 |
| TRANSCRIPT | 2025-09-30 | 7 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,122.00 | 754.00 | 652.00 | 724.00 | 903.00 | 542.00 | 674.00 | 839.00 | 988.00 | 642.00 | 679.00 | 1,057.00 | 930.00 | 568.00 | 684.00 | 1,063.00 |
| Other income | 11.00 | 13.00 | 16.00 | 18.00 | 25.00 | 27.00 | 27.00 | 26.00 | 31.00 | 31.00 | 32.00 | 39.00 | 39.00 | 37.00 | 32.00 | 47.00 |
| Total income | 1,132.00 | 767.00 | 668.00 | 742.00 | 928.00 | 569.00 | 701.00 | 865.00 | 1,020.00 | 673.00 | 711.00 | 1,096.00 | 969.00 | 605.00 | 716.00 | 1,111.00 |
| Cost of materials consumed | 583.00 | 352.00 | 404.00 | 446.00 | 338.00 | 231.00 | 392.00 | 385.00 | 453.00 | 334.00 | 420.00 | 445.00 | 455.00 | 331.00 | 420.00 | 554.00 |
| Purchases of stock-in-trade | 78.00 | 62.00 | 58.00 | 70.00 | 55.00 | 78.00 | 77.00 | 76.00 | 87.00 | 80.00 | 73.00 | 112.00 | 71.00 | 14.00 | 39.00 | 132.00 |
| Changes in inventories | 36.00 | 74.00 | -15.00 | -17.00 | 164.00 | 17.00 | -76.00 | 52.00 | 28.00 | -43.00 | -86.00 | 98.00 | 4.00 | -46.00 | -64.00 | -40.00 |
| Employee benefit expense | 54.00 | 52.00 | 54.00 | 60.00 | 59.00 | 54.00 | 59.00 | 66.00 | 66.00 | 68.00 | 65.00 | 71.00 | 70.00 | 65.00 | 68.00 | 73.00 |
| Finance costs | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Depreciation and amortisation | 15.00 | 11.00 | 14.00 | 14.00 | 16.00 | 16.00 | 17.00 | 15.00 | 16.00 | 19.00 | 16.00 | 16.00 | 17.00 | 17.00 | 17.00 | 17.00 |
| Other expenses | 93.00 | 94.00 | 69.00 | 85.00 | 100.00 | 96.00 | 82.00 | 100.00 | 109.00 | 96.00 | 88.00 | 112.00 | 113.00 | 104.00 | 87.00 | 110.00 |
| Total expenses | 860.00 | 646.00 | 586.00 | 658.00 | 733.00 | 494.00 | 552.00 | 694.00 | 760.00 | 557.00 | 578.00 | 855.00 | 731.00 | 487.00 | 568.00 | 849.00 |
| Profit before exceptional items and tax | 272.00 | 121.00 | 82.00 | 83.00 | 195.00 | 75.00 | 149.00 | 171.00 | 260.00 | 117.00 | 133.00 | 241.00 | 238.00 | 118.00 | 148.00 | 261.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -16.00 | 0.00 | 27.00 |
| Profit before tax | 272.00 | 121.00 | 82.00 | 83.00 | 195.00 | 75.00 | 149.00 | 171.00 | 260.00 | 117.00 | 133.00 | 241.00 | 238.00 | 102.00 | 148.00 | 288.00 |
| Current tax | 68.00 | 31.00 | 25.00 | 21.00 | 49.00 | 18.00 | 35.00 | 44.00 | 66.00 | 28.00 | 31.00 | 62.00 | 59.00 | 26.00 | 37.00 | 74.00 |
| Deferred tax | 2.00 | -0.00 | -15.00 | 1.00 | 3.00 | 2.00 | 4.00 | 1.00 | 1.00 | 1.00 | 2.00 | 0.00 | 1.00 | -0.00 | -1.00 | -1.00 |
| Tax expense | 71.00 | 30.00 | 9.00 | 22.00 | 52.00 | 21.00 | 39.00 | 44.00 | 67.00 | 29.00 | 33.00 | 62.00 | 60.00 | 26.00 | 36.00 | 74.00 |
| Profit for the period | 201.00 | 90.00 | 72.00 | 62.00 | 143.00 | 55.00 | 110.00 | 127.00 | 193.00 | 87.00 | 100.00 | 178.00 | 178.00 | 76.00 | 111.00 | 215.00 |
| Profit attributable to owners | 201.00 | 90.00 | 72.00 | 62.00 | 143.00 | 55.00 | 110.00 | 127.00 | 192.00 | 87.00 | 100.00 | 178.00 | 178.00 | 76.00 | 111.00 | 215.00 |
| Profit attributable to non-controlling interests | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | 0.00 | 0.00 | -0.00 |
| Other comprehensive income | 0.00 | -1.00 | 1.00 | -0.00 | -1.00 | 1.00 | -0.00 | 0.00 | -3.00 | 1.00 | 0.00 | -1.00 | 1.00 | 5.00 | 0.00 | -1.00 |
| Total comprehensive income | 202.00 | 89.00 | 73.00 | 61.00 | 143.00 | 55.00 | 110.00 | 127.00 | 190.00 | 89.00 | 100.00 | 177.00 | 179.00 | 81.00 | 112.00 | 214.00 |
| Earnings per share, basic | 4.04 | 1.81 | 1.45 | 1.24 | 2.87 | 1.10 | 2.20 | 2.54 | 3.85 | 1.74 | 2.00 | 3.57 | 3.56 | 1.52 | 2.23 | 4.30 |
| Earnings per share, diluted | 4.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 0.00 | 3.56 | 0.00 | 2.23 | 0.00 |
Annual results, as filed
| Line | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|
| Revenue from operations | 2,425.00 | 2,645.00 | 3,065.00 | 3,511.00 | 2,844.00 | 3,149.00 | 3,238.00 |
| Other income | 11.00 | 19.00 | 27.00 | 45.00 | 96.00 | 120.00 | 147.00 |
| Total income | 2,435.00 | 2,663.00 | 3,091.00 | 3,556.00 | 2,940.00 | 3,269.00 | 3,385.00 |
| Cost of materials consumed | 1,287.00 | 1,565.00 | 1,848.00 | 1,857.00 | 1,407.00 | 1,592.00 | 1,651.00 |
| Purchases of stock-in-trade | 191.00 | 209.00 | 231.00 | 267.00 | 280.00 | 316.00 | 235.00 |
| Changes in inventories | 129.00 | -118.00 | -171.00 | 146.00 | 89.00 | -49.00 | -8.00 |
| Employee benefit expense | 179.00 | 194.00 | 202.00 | 218.00 | 232.00 | 265.00 | 274.00 |
| Finance costs | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 8.00 |
| Depreciation and amortisation | 41.00 | 47.00 | 45.00 | 52.00 | 62.00 | 66.00 | 66.00 |
| Other expenses | 305.00 | 308.00 | 355.00 | 355.00 | 362.00 | 393.00 | 416.00 |
| Total expenses | 2,138.00 | 2,210.00 | 2,516.00 | 2,902.00 | 2,437.00 | 2,588.00 | 2,641.00 |
| Profit before exceptional items and tax | 297.00 | 453.00 | 576.00 | 654.00 | 503.00 | 680.00 | 744.00 |
| Exceptional items | -31.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -16.00 |
| Profit before tax | 267.00 | 453.00 | 576.00 | 654.00 | 503.00 | 680.00 | 728.00 |
| Current tax | 75.00 | 102.00 | 143.00 | 167.00 | 123.00 | 169.00 | 184.00 |
| Deferred tax | -14.00 | 6.00 | 9.00 | -15.00 | 10.00 | 5.00 | 0.00 |
| Tax expense | 62.00 | 108.00 | 152.00 | 152.00 | 133.00 | 174.00 | 185.00 |
| Profit for the period | 205.00 | 345.00 | 424.00 | 502.00 | 370.00 | 506.00 | 543.00 |
| Profit attributable to owners | 0.00 | 0.00 | 424.00 | 502.00 | 370.00 | 505.00 | 543.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | -0.00 | — | 0.00 | 1.00 | 0.00 |
| Other comprehensive income | -5.00 | 2.00 | 2.00 | 2.00 | -0.00 | -1.00 | 6.00 |
| Total comprehensive income | 200.00 | 347.00 | 426.00 | 504.00 | 369.00 | 505.00 | 549.00 |
| Earnings per share, basic | 4.10 | 6.92 | 8.49 | 10.06 | 7.40 | 10.13 | 10.88 |
| Earnings per share, diluted | 4.10 | 6.92 | 8.49 | 0.00 | 0.00 | 10.13 | 10.88 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 3,455.00 | 3,369.00 | 3,528.00 | 3,313.00 | 3,843.00 | 3,964.00 | 4,439.00 | 4,474.00 |
| Non-current assets | 590.00 | 581.00 | 585.00 | 640.00 | 728.00 | 944.00 | 894.00 | 1,134.00 |
| Current assets | 2,865.00 | 2,788.00 | 2,943.00 | 2,673.00 | 3,114.00 | 3,020.00 | 3,545.00 | 3,340.00 |
| Property, plant and equipment | 379.00 | 393.00 | 450.00 | 466.00 | 451.00 | 426.00 | 409.00 | 437.00 |
| Capital work-in-progress | 23.00 | 53.00 | 23.00 | 4.00 | 9.00 | 9.00 | 14.00 | 3.00 |
| Goodwill | 0.00 | 0.00 | 28.00 | 62.00 | 60.00 | 60.00 | 60.00 | 60.00 |
| Other intangible assets | 35.00 | 0.00 | 4.00 | 6.00 | 6.00 | 7.00 | 8.00 | 8.00 |
| Inventories | 818.00 | 889.00 | 562.00 | 610.00 | 564.00 | 704.00 | 613.00 | 766.00 |
| Trade receivables | 1,185.00 | 946.00 | 868.00 | 716.00 | 944.00 | 783.00 | 903.00 | 736.00 |
| Cash and cash equivalents | 81.00 | 47.00 | 51.00 | 47.00 | 53.00 | 38.00 | 41.00 | 69.00 |
| Total equity and liabilities | 3,455.00 | 3,369.00 | 3,528.00 | 3,313.00 | 3,843.00 | 3,964.00 | 4,439.00 | 4,474.00 |
| Equity | 2,220.00 | 2,382.00 | 2,526.00 | 2,445.00 | 2,717.00 | 2,905.00 | 3,201.00 | 3,394.00 |
| Equity share capital | 499.00 | 499.00 | 499.00 | 499.00 | 499.00 | 499.00 | 499.00 | 499.00 |
| Other equity | 1,721.00 | 1,883.00 | 2,027.00 | 1,942.00 | 2,214.00 | 2,402.00 | 2,698.00 | 2,891.00 |
| Total liabilities | 1,235.00 | 987.00 | 1,002.00 | 869.00 | 1,126.00 | 1,059.00 | 1,237.00 | 1,080.00 |
| Non-current liabilities | 42.00 | 54.00 | 57.00 | 68.00 | 79.00 | 94.00 | 102.00 | 111.00 |
| Current liabilities | 1,194.00 | 933.00 | 946.00 | 801.00 | 1,046.00 | 965.00 | 1,136.00 | 970.00 |
| Borrowings, non-current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 |
| Borrowings, current | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 19.00 | 21.00 | 0.00 |
| Trade payables | 550.00 | 491.00 | 440.00 | 430.00 | 490.00 | 489.00 | 484.00 | 397.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 308.00 | 389.00 | 644.00 | 760.00 | 187.00 | 453.00 | 435.00 | 446.00 |
| Net cash from investing activities | -223.00 | -327.00 | -569.00 | -432.00 | -299.00 | -392.00 | -360.00 | -332.00 |
| Net cash from financing activities | -61.00 | -73.00 | -71.00 | -328.00 | -53.00 | -69.00 | -73.00 | -83.00 |
| Purchase of property, plant and equipment | 59.00 | 120.00 | 46.00 | 66.00 | 12.00 | 29.00 | 15.00 | 44.00 |
| Net increase in cash | 24.00 | -10.00 | 4.00 | -0.00 | -165.00 | -8.00 | 3.00 | 31.00 |
| con:CFO.BEFORE_TAX | 381.00 | 557.00 | 707.00 | 889.00 | 258.00 | 617.00 | 508.00 | 609.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 73.00 | 168.00 | 63.00 | 129.00 | 71.00 | 164.00 | 73.00 | 164.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 2.00 | 2.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 75.00 | 75.00 | 75.00 | 75.00 | 75.00 | 75.00 | 75.00 | 75.00 | 75.00 | 75.00 | 0.75 | 0.75 | 0.75 | 0.75 |
| Domestic institutions | 5.51 | 5.50 | 6.07 | 6.02 | 6.64 | 7.14 | 6.97 | 6.96 | 8.14 | 8.15 | 0.08 | 0.09 | 0.09 | 0.09 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 6.16 | 0.07 | 0.07 | 0.07 | 0.07 |
| Insurance companies | 1.94 | 1.73 | 1.83 | 1.87 | 1.96 | 1.76 | 1.23 | 1.10 | 1.20 | 1.15 | 0.01 | 0.01 | 0.01 | 0.01 |
| Foreign institutions | 2.40 | 2.52 | 2.58 | 2.61 | 2.75 | 3.07 | 3.49 | 3.59 | 3.63 | 3.65 | 0.04 | 0.03 | 0.03 | 0.03 |
| Government | — | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Public | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 0.25 | 0.25 | 0.25 | 0.25 |
| Non-institutional | 17.09 | 16.98 | 16.35 | 16.36 | 15.62 | 14.79 | 14.54 | 14.45 | 13.23 | 13.20 | 0.13 | 0.13 | 0.13 | 0.13 |
| Shares outstanding | 499145736 | 499145736 | 499145736 | 499145736 | 499145736 | 499145736 | 499145736 | 499145736 | 499145736 | 499145736 | 499145736 | 499145736 | 499145736 | 499145736 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Sumitomo Chemical Company, Limited | Holding Company | Any other transaction, Purchase of goods or services | 2,184,130,000.00 | 3 |
| Sumitomo Chemical Brazil Industria Quimika S A | Fellow Subsidiary | Purchase of goods or services, Sale of goods or serv | 1,119,620,000.00 | 2 |
| Sumitomo Chemical Company Limited | Holding Company | Sale of goods or services | 584,130,000.00 | 1 |
| Valent BioSciences LLC | Fellow Subsidiary | Purchase of goods or services | 227,610,000.00 | 1 |
| Sumitomo Chemical Agro Europe S.A.S. | Fellow Subsidiary | Sale of goods or services | 34,650,000.00 | 1 |
| Mr. Chetan Shah | Managing Directors | Remuneration | 29,720,000.00 | 1 |
| Mr. Sushil Marfatia | Executive Directors | Remuneration | 11,360,000.00 | 1 |
| Sumitomo Chemical India Gratuity Trust | Post Employment Benefit Plans enti | Any other transaction | 11,280,000.00 | 1 |
| Sumitomo Chemical India Superannuation Trust | Post Employment Benefit Plans enti | Any other transaction | 10,290,000.00 | 1 |
| Dr Suresh Ramachandran | Whole-time Director & CCO | Remuneration | 8,830,000.00 | 1 |
| Mr. Anil Nawal | Chief Financial Officer | Remuneration | 8,290,000.00 | 1 |
| Sumitomo Chemical Argentina SA | Fellow Subsidiary | Sale of goods or services | 7,750,000.00 | 1 |
| Sumitomo Chemical Asia Pte Limited | Fellow Subsidiary | Sale of goods or services | 3,620,000.00 | 1 |
| Ms Deepika Trivedi | Company Secretary | Remuneration | 1,290,000.00 | 1 |
| Kanga & Company | Enterprises controlled by key mana | Purchase of goods or services | 180,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-06-04 | Q4FY26 | DIRECTOR, PLANNING AND COORDINATION OFFICE | Read the call |
| 2024-06-03 | Q4FY24 | COMPLIANCE OFFICER | Read the call |
| 2023-05-25 | Q4FY23 | SUMITOMO CHEMICAL INDIA LIMITED | Read the call |
| 2021-06-06 | Q4FY21 | LIMITED, SUMITOMO CHEMICAL INDIA LIMITED | Read the call |
What they said about it, quarter by quarter
| Topic | Q4FY21 | Q4FY23 | Q4FY24 | Q4FY26 |
|---|---|---|---|---|
| Capex | In addition to the regular CAPEX requirements, we plan to manufacture in India few of the products for our parent company, SCC, and our global affilia… | This is over and above the normal and routine capex, which we have been incurring for our existing products and businesses. | Congrats on good Q4. The first question is on the capex and project. | On our capital expenditure program, we want to reconfirm our commitment to invest in infrastructure for expanding our manufacturing portfolio, especia… |
| Capital allocation | What figure you are talking about is of Sumitomo’s acquisition of Nufarm in Latin America and what is the upside over there. | My second question was that Sumitomo Japan has recently made this acquisition in the biostimulant space. | — | — |
| Costs | No, we are not facing any issue on procuring the raw materials. | The input cost prices are at lower level and profitability should return to normal levels in next couple of months and when weighted average of invent… | And in Q3, we started buying the raw materials at lower prices which gave us a tremendous cost advantage, which in the fourth quarter, when we started… | As cost pressures have built already and continue to build, the company has been gradually and systematically passing on these increases to the market… |
| Debt and cash | So we achieved overall decrease in the working capital cycle to 103 days in Financial Year ’20-21 from 115 days in Financial Year ’19-20. | Our net working capital stood at 124 days in financial year '22, '23 as compared to 133 days in financial year '22. | As a matter of fact, our group companies because of the global situation and as per the directives of SCC Japan, we are actually in the mode of reduci… | On working capital, our net working capital stood at 103 days as of 31st March 2026 versus 89 days a year ago. |
| Demand | Agrochemical industries capacity utilization also has seen improved performance on the back of greater domestic demand and growing export opportunitie… | The company has received regulatory approval for selected products, which have exhibited robust demand and will serve as a strong base for expansion o… | Sir, internationally, how are you seeing the demand for us? | The interim reduction in animal nutrition distribution revenues and the adverse agro-climatic condition that suppressed industry-wide demand through t… |
| Guidance | If we talk about our overall resources from SCC side, there is a lot of guidance, support, and the global knowhow which is available to us to access b… | We anticipate good growth, stability and profitability in the herbicides, PGR and biorational product segments. | So my first question is what would be your guidance for FY '25? | We expect this share and absolute revenue contribution to grow meaningfully from FY27 onwards as the new framework takes full effect. |
| Margin | EBITDA margin in the current quarter widened by 407 basis points to 13.4% from 9.3% in Q4 FY ’19-20. | Our EBITDA margins were 19% in financial year '22, '23 as compared to 19.6% in the previous year. | Sir, on -- in Q4, we have seen a very sharp gross margin expansion. | Our branded formulation share in domestic sales improved to 81% in FY '26 from 79% in FY '25, reflecting the ongoing structural shift towards higher q… |
| Pricing | On pricing, whether is there a contractual agreement? | In all the segments, we delivered price increases. | So our purchasing in the Q4 for the coming quarters also has been at a very, very good level, very good pricing. | On cost and pricing, FY '27 will be characterized by headwinds from depreciating rupee, escalating cost across raw materials, packaging materials, sol… |
| Revenue growth | These new launches will aid in our growth apart from the growth of the existing portfolio of products. | The growth of our domestic agro-solutions business was primarily driven by price appreciation in FY '22-'23. | And in terms of volume growth, I think that was your specific question, at least we want to compensate whatever is the price (inaudible) needs to be c… | The headline revenue growth of 3% for FY '26 understates the underlying momentum of the core crop protection business for two reasons. |